Racura Oncology says a new formulation of its lead drug bisantrene delivers the same drug exposure as the earlier version used in two acute myeloid leukaemia trials. The company says this lets it draw on that clinical record as it moves the new product into a Phase 2b/3 study.
The Sydney company today reported the results of a Good Laboratory Practice pharmacokinetic bridging study. The study compared RC220, its proprietary formulation of (E,E)-bisantrene, with RC110, the earlier formulation used in two investigator-led trials in patients with relapsed or refractory AML. It found the two produced equivalent systemic exposure to the drug.
The two products share the same active ingredient and differ only in their inactive ingredients. RC220 was developed so bisantrene could be given through a peripheral vein in the arm or leg rather than through a central line, a catheter placed in a large vein near the heart.
When a drug is reformulated in this way, a company needs evidence that the new product delivers the same exposure to the active drug before it can rely on experience with the older version. A bridging study is designed to answer that question.
Racura chief executive and managing director Dr Daniel Tillett said the study was designed to establish whether RC220 delivers the same drug exposure as RC110. "The results of this GLP PK study show the two formulations delivered equivalent exposure to (E,E)-bisantrene," he said. "The findings provide an important bridge to the clinical experience with RC110, which produced a 40 per cent response rate in two separate Phase 2 trials in heavily pre-treated AML patients. This bridging study supports our plans to evaluate RC220 in patients with AML in the Phase 2b/3 EMILI trial as well as our HARNESS and CPACS clinical programs."
The study used six male Beagle dogs in a crossover design. Each animal received both formulations in random order with a five-day washout in between, so each served as its own control. Each formulation was given as a 30-minute intravenous infusion at 1 mg/kg once daily for three consecutive days. This matched the daily dosing used in the earlier AML trials and planned for RC220. Frequent blood samples tracked plasma levels over time.
Equivalence was judged using the standard approach set out by the US Food and Drug Administration and the European Medicines Agency. Under that approach, the 90 per cent confidence interval for the ratio of average exposure must fall entirely between 0.80 and 1.25, meaning exposure differs by no more than 20 per cent either way. Racura said the intervals for both peak plasma concentration and total exposure fell within that range on every dosing day. The geometric mean ratios ranged from 0.971 to 1.057, where a ratio of 1.00 indicates identical exposure.
The company said dogs are a standard species for this kind of work and were one of the two species used in RC220's toxicology program. It said no animal was harmed because the doses were well below harmful levels.
The clinical record Racura wants to carry across comes from two trials at the Sheba Medical Center in Israel. In a Phase 2 trial, RC110 given alone produced an overall response rate of 40 per cent in 10 patients. In a Phase 1b/2 trial, RC110 combined with fludarabine and clofarabine produced a response in six of 15 evaluable patients. Those results underpin the company's plan to advance RC220 in AML through the EMILI trial, which it announced a year ago.
Patients are already receiving RC220 through a peripheral vein in two Phase 1 trials, CPACS in solid tumours and HARNESS in lung cancer. Racura said the bridging results were not essential to running those trials but may help speed up dose escalation or support an earlier move to later-stage studies.